Pfizer Says Eliquis Sales Rose 25% in Third Quarter
Pfizer said Eliquis sales gained 25% in the third quarter, driven by higher U.S. prices and stronger global demand. The company is bracing for the blood thinner to lose patent protection.
Pfizer said Eliquis sales gained 25% in the third quarter, driven by higher U.S. prices and stronger global demand. The company is bracing for the blood thinner to lose patent protection.